3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 3
2
Phase 2
2
Phase 1/2
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Advanced Solid Tumor
13
Leukemia, Myeloid, Acute
10
Carcinoma, Non-Small-Cell Lung
7
Advanced Solid Tumors
7
Breast Neoplasms
6
Solid Tumor
5
Pancreatic Neoplasms
5
Melanoma
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
4
Neoplasm Metastasis
4
Lymphoma, Non-Hodgkin
4
Solid Tumors
3
Recurrence
3
Myelodysplastic Syndromes
3
Lung Neoplasms
3
Leukemia, Biphenotypic, Acute
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Biliary Tract Neoplasms
3
Advanced Malignant Solid Tumor
3
Advanced Lung Cancer
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Prostatic Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Interventions
Etoposide
18
Carboplatin
18
pembrolizumab
15
Nivolumab
11
Cisplatin
11
atezolizumab
8
Topotecan
8
Irinotecan
7
Temozolomide
6
Paclitaxel
5
PM 01183
5
Ipilimumab
5
Gemcitabine
5
olaparib
4
Radiotherapy
4
Docetaxel
4
surufatinib
3
durvalumab
3
carfilzomib
3
Bevacizumab
3
veliparib
2
trilaciclib
2
sacituzumab govitecan
2
rovalpituzumab tesirine
2
obatoclax
2
niraparib
2
navitoclax
2
lorvotuzumab mertansine
2
lenvatinib
2
fluzoparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Small Cell Lung Carcinoma
×
Injections
×
Clear all
NCT04487756
2026-06-02
VENEZO-LUNG
Instituto Oncológico Dr Rosell
Phase 1/2
Completed
20 enrolled
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled